TL;DR: The Centers for Medicare & Medicaid Services modified NCD 188, the National Coverage Determination governing Medicare coverage of histocompatibility testing, effective March 7, 2026. Here's what changes for billing teams.
CMS updated NCD 188 to clarify the covered indications for human leukocyte antigen (HLA) typing and matching — the testing performed before kidney transplants, bone marrow transplants, platelet transfusions, and for suspected ankylosing spondylitis. This policy does not list specific CPT or HCPCS codes, which creates documentation and claim-level challenges your billing team needs to address now, before March 7, 2026. If your practice or facility bills for transplant workup labs, transfusion medicine, or rheumatologic testing, this modification is directly in your lane.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Histocompatibility Testing |
| Policy Code | NCD 188 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Nephrology, Transplant Surgery, Hematology/Oncology, Transfusion Medicine, Rheumatology, Diagnostic Laboratory |
| Key Action | Audit your ankylosing spondylitis HLA claims for documentation of medical necessity before March 7, 2026 — CMS requires supporting documentation in every case where AS is the stated reason |
CMS Histocompatibility Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 188 is the National Coverage Determination governing whether Medicare covers histocompatibility testing — specifically HLA typing and matching — and under what clinical circumstances. The modified policy confirms four covered indications, but the standard for "reasonable and necessary" is applied differently depending on which indication you're billing.
For three of the four indications, coverage is straightforward. CMS covers HLA testing for patients preparing for a kidney transplant, patients preparing for bone marrow transplantation, and patients receiving blood platelet transfusions — particularly where multiple infusions are involved. If the clinical scenario fits one of these three categories and the test is reasonable and necessary for the patient, Medicare reimbursement is supported under NCD 188.
The fourth indication — suspected ankylosing spondylitis — has a harder coverage standard. CMS covers HLA-B27 testing for ankylosing spondylitis only when other diagnostic methods are not appropriate or have already produced inconclusive results. That's a sequential logic requirement, not just a clinical preference. You can't lead with the HLA test and justify it afterward.
The real issue is documentation. For every ankylosing spondylitis claim, CMS explicitly requires you to obtain documentation from the physician supporting medical necessity. That's not a soft recommendation — it's a stated coverage requirement in the policy. If that documentation isn't in the record before you submit the claim, you're exposed to denial.
CMS Histocompatibility Testing Exclusions and Non-Covered Indications
The policy limits coverage to the four indications listed. Testing ordered outside those four clinical contexts — or for ankylosing spondylitis without evidence that other diagnostic methods were attempted or ruled out first — does not meet the medical necessity standard under NCD 188.
The ankylosing spondylitis indication is the one most likely to generate claim denials in practice. "Suspected" diagnosis alone isn't enough. The coverage policy requires that other diagnostic methods either weren't appropriate for this specific patient or produced inconclusive results. If your ordering physician didn't document why alternative methods were bypassed, your claim is vulnerable — regardless of the clinical rationale that may exist in the physician's head.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Preparation for kidney transplant | Covered | Not specified in policy | Must be reasonable and necessary for the patient |
| Preparation for bone marrow transplantation | Covered | Not specified in policy | Must be reasonable and necessary for the patient |
| Blood platelet transfusions (especially multiple infusions) | Covered | Not specified in policy | Must be reasonable and necessary for the patient |
| Suspected ankylosing spondylitis | Covered — with conditions | Not specified in policy | Covered only when other diagnostic methods were not appropriate or yielded inconclusive results; physician documentation of medical necessity required on every claim |
CMS Histocompatibility Testing Billing Guidelines and Action Items 2026
The policy modification is effective March 7, 2026. These are the actions your billing team should complete before that date.
| # | Action Item |
|---|---|
| 1 | Audit your current ankylosing spondylitis HLA claims. Pull any claims in your pipeline or recently submitted that used suspected AS as the indication. Confirm that each one has physician documentation on file stating why alternative diagnostic methods weren't appropriate or were inconclusive. If that documentation is missing, get it before submission. |
| 2 | Build a documentation checklist for AS-indicated HLA orders. Your front-end intake or lab order process should flag any HLA order tied to a rheumatologic indication and require the ordering physician to supply a written justification — not a checkbox, but a clinical narrative. This should be in place before March 7, 2026. |
| 3 | Confirm with your compliance officer how "reasonable and necessary" is being applied to transplant and transfusion cases. The coverage policy is permissive for those three indications, but "reasonable and necessary" is still a live standard. If your facility bills high volumes of pre-transplant HLA testing, your compliance officer should review whether your documentation practices match that standard. |
| 4 | Identify which CPT or HCPCS codes your lab uses for HLA testing and map them to the four covered indications. NCD 188 does not enumerate specific codes — which means your MAC (Medicare Administrative Contractor) may have its own Local Coverage Determination (LCD) that does. Contact your MAC or check the CMS LCD database for any companion local policy that specifies billing codes. Do this before March 7, 2026. |
| 5 | Brief your rheumatology and transplant medicine billing teams separately. The ankylosing spondylitis pathway has a different documentation requirement than the transplant and transfusion pathways. A single internal training session that treats all four indications identically will miss that distinction and leave your AS claims exposed. |
| 6 | Set up a claim denial tracking flag for NCD 188. If you start seeing denials citing "not reasonable and necessary" or "indication not covered" on HLA claims after March 7, 2026, you want to catch that pattern early. Add NCD 188 as a filter in your denial management workflow. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Histocompatibility Testing Under NCD 188
No Codes Listed in NCD 188
NCD 188, as modified with the March 7, 2026 effective date, does not enumerate specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older National Coverage Determinations, but it creates a real operational problem for billing teams.
The absence of specific codes in the NCD means you're billing into a policy that sets clinical indications without telling you which codes trigger it. In practice, your coverage and claim-level decisions will depend on your MAC's local coverage policy, any associated LCD, and the diagnosis codes your physician uses to support the order.
Do not fabricate or assume codes based on the NCD alone. Work with your MAC and your billing consultant to identify the specific codes in use at your facility for HLA typing and matching, then confirm their coverage status under both NCD 188 and any applicable LCD. If you're not sure where to start, that conversation belongs with your compliance officer or revenue cycle consultant before March 7, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.